ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2024
ANCA-associated vasculitis-treatment standard.
Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- A critical appraisal of guidelines and recommendations for the management of ANCA-associated vasculitis.Clinical kidney journal · 2026Article
- Article
- [From sudden hearing loss to an inflammatory systemic disease].Innere Medizin (Heidelberg, Germany) · 2026Article
- Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe kidney involvement.Clinical kidney journal · 2026Article
- Psychological Aspects of Rheumatic Diseases: Psychorheumatology in Clinical Practice.Rheumatology and therapy · 2026Review
- Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A European Multicenter Study.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Antineutrophilic Cytoplasmic Antibodies Negative Vasculitic Neuropathy.Annals of African medicine · 2026Article
- New-Onset ANCA-Associated Vasculitis in Pregnancy Successfully Treated With Rituximab: A Case Report and Literature Review.Kidney medicine · 2026Article
- Advances in the Diagnosis, Treatment and Prognosis of ANCA-Associated Glomerulonephritis.Medicina (Kaunas, Lithuania) · 2026Review
- A Rare Presentation of Granulomatosis With Polyangiitis: A Case Report and Literature Review.Clinical case reports · 2026Article
- Article
- Real-world outcomes of avacopan beyond the first year in antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study.BMC rheumatology · 2026Article
- Systematic Review of Efficacy and Safety of Avacopan in Real-World Clinical Practice.Kidney international reports · 2026Article
- The Role of Kidney Biopsy as a Tool for Personalized Treatment Decision-Making in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Nephritis.Journal of personalized medicine · 2026Article
- Trends in mortality due to GPA/MPA across Europe: insights from a decade of death registrations.Rheumatology (Oxford, England) · 2026Article
- Avacopan for severe pulmonary hemorrhage requiring extracorporeal membrane oxygenation in a patient with MPO-ANCA positive vasculitis.CEN case reports · 2026Article
- Addressing clinical challenges in ANCA-associated vasculitis with real-world evidence.Rheumatology (Oxford, England) · 2026Review
- Avacopan in the treatment of relapsing polychondritis with myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis: A case report.World journal of nephrology · 2025Article
- Predicting prognosis in ANCA-associated vasculitis with kidney involvement.Clinical kidney journal · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are characterized by small-vessel necrotizing inflammation, and prior to the advent of immunosuppressive therapy frequently had a fatal outcome. Treatment has transformed AAV into a relapsing/remitting disease with increased drug-related toxicities and organ damage. The use of glucocorticoids, cyclophosphamide and immunosuppressives (including azathioprine, mycophenolate and methotrexate) was optimized through a sequence of clinical trials establishing a standard of care against which subsequent targeted therapies could be developed. Improved understanding of pathophysiology has supported the development of B-cell depletion and complement inhibition in granulomatosis with polyangiitis and microscopic polyangiitis, and interleukin 5 inhibition for eosinophilic granulomatosis with polyangiitis, leading to the approval of newer agents for these conditions. There has been an increased attention on minimizing the adverse effects of treatment and on understanding the epidemiology of comorbidities in AAV. This review will focus on recent evidence from clinical trials, especially with respect to glucocorticoids, avacopan, plasma exchange, rituximab and mepolizumab, and their interpretation in the 2022 management recommendations by the European League of Associations of Rheumatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.